V-POL Audit: Teva Pharmaceuticals

Corporate Communications & Public Stance

CEO Richard Francis issued a public statement on October 11, 2023 expressing solidarity with Israel following the October 7 attacks, describing them as “unprecedented, horrific, and brutal attacks on Israeli civilians” ¹². The October 2023 statement made no reference to Palestinian civilian harm, called for no ceasefire, and expressed no humanitarian concern for Gaza ¹. Following the October 2023 mobilization, Teva acknowledged that nearly 10% of its Israeli workforce (~338 employees) were called to military reserve duty; the CEO stated “our production remains unaffected” ³. No public corporate statements addressing Gaza, humanitarian access, or ceasefire were identified for 2024-2025 period despite ongoing conflict ¹. Comparative analysis shows Teva issued a March 2022 statement announcing an $11 million donation of essential medicines for Ukrainian refugees ⁴, demonstrating more substantial humanitarian engagement for Ukraine than for Gaza.

Operations in Occupied or Contested Territories

Teva is not listed in the UN OHCHR Business and Human Rights Database of companies involved in Israeli settlement activities ⁵; this was confirmed across all three research rounds despite 2016-2019 discussions about potential listing. Teva’s primary facilities are located within Israel’s pre-1967 borders (Ashdod manufacturing, national distribution network) ⁶. The Who Profits Research Center documents Teva’s involvement in what it terms the “Palestinian captive market”—the system whereby Israeli policies restrict Palestinian access to pharmaceutical imports, creating a protected market for Israeli companies ⁶⁷. Salomon, Levin & Elstein (S.L.E.) operates as Teva’s Israeli distribution subsidiary ⁸; the geographic scope of its operations encompasses all of Israel and the OPT, though specific settlement-area warehouse locations were not confirmed. KPMG’s December 2024 report, commissioned by Norwegian hospital procurement agency Sykehusinnkjøp HF, examined Teva’s involvement in the Palestinian pharmaceutical market and noted discussions around UN settlement blacklist inclusion ⁹.

Internal Governance, Content & Retail Policies

Teva’s corporate governance framework (Code of Business Conduct and Ethics, board committee charters) addresses anti-corruption, supply chain integrity, and regulatory compliance but contains no specific provisions addressing operations in contested territories ⁶. Annual ESG and corporate responsibility reports address labor standards, access to medicines, and environmental compliance without addressing human rights risks associated with Israeli operations in occupied territories ⁶. Teva operates as a pharmaceutical manufacturer rather than a consumer-facing platform—product distribution occurs through institutional, pharmacy, and healthcare-system channels. No public evidence identified of internal employee policy controversies, leaked communications, or staff organizing related to the Israel-Gaza conflict.

Brand Heritage & State Partnerships

Teva was founded in Jerusalem in 1901; its name derives from the Hebrew word for “nature,” embedding Israeli heritage in corporate identity ⁶. Teva is Israel’s largest private-sector employer; headquarters remain in Petach Tikva, Israel ⁶. Teva participates in the Rise innovation program—a $10 million partnership with the Israel Innovation Authority (IIA) and Startup Nation Central—accepting applications through 2025 ¹⁰¹¹¹². Teva has received standard R&D tax incentives from Israeli government bodies, available to all qualifying Israeli technology companies ⁶. No evidence identified of formal participation in Israeli government “Brand Israel” public diplomacy campaigns. Declassified UK reported that IDF honored Teva in 2009 for “exemplary” relationship with reservist employees ¹³.

Lobbying, Advocacy, Financing & Logistics

Teva Pharmaceuticals USA is a registered federal lobbyist under the Lobbying Disclosure Act; spending totaled $2.13 million in 2023 and $2.25 million in 2024 ¹⁴. Senate LDA filings (2017-2022) show issue codes exclusively covering domestic healthcare policy: drug pricing, Medicare/Medicaid, FDA regulatory matters—none related to foreign policy or Israel ¹⁵. Teva operates a federal PAC that contributed $58,500 to federal candidates in the 2023-2024 cycle; recipient lists show no specific correlation with Israel-related policy positions ¹⁶. Teva is a member of PhRMA and the Association for Accessible Medicines; both focus on pharmaceutical pricing and regulatory policy. Anti-BDS certification requirements in Texas and Florida apply to Teva as a Medicaid supplier; however, the Texas anti-BDS law was ruled unconstitutional by a federal court in 2022 ¹⁷.

Corporate Structure & Primary Mission

Teva Pharmaceutical Industries Ltd. is incorporated in Israel and listed on NYSE (TEVA) and TASE—the world’s largest generic pharmaceutical manufacturer by volume ⁶. Corporate charter establishes a commercial pharmaceutical mission: developing, manufacturing, and distributing generic and branded medicines globally ⁶. No state-directed mandate, golden share arrangement, or Israeli government ownership stake identified ⁶. Operations span approximately 60 countries; substantial revenue from US and Europe with Israeli domestic market representing a smaller share.

Executive & Leadership Footprint

CEO Richard Francis (since 2023) is a British national with pharmaceutical industry background at Biogen and Sandoz—no documented personal affiliations with FIDF, JNF/KKL, or AIPAC identified ¹⁸. Chairman Rosemary Crane has pharmaceutical industry background (MELA Sciences, Epocrates, Catalent, Tarsus); no identified defense-industry or settlement-NGO ties ¹⁹. Teva Cares Foundation (501(c)(3), EIN 26-3977456, Parsippany, NJ) reported $288.7 million revenue and $172.1 million charitable disbursements in 2024 ²⁰; Schedule B recipient details not visible in public summary. REPILL’s June 2025 report documents Teva’s relationship with Israeli Defense Forces since October 7, 2023 ²¹. BDS Movement and Health Care Workers for Palestine have called for institutional boycotts of Teva ²².

End Notes